



Crescendo Biologics Presenting at Key Industry Events during October 2019

Cambridge, UK, 16 October 2019 – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T cell enhancing therapeutics, confirms upcoming attendance at the following conferences during October 2019:

- [The Research & Technology Series: Immuno-oncology](#), 10-11 October, London, UK

The Research & Technology Series: Immuno-oncology will focus on recent scientific and technological advances in novel cancer targets, biomarker detection and large molecule immuno-oncology.

Crescendo's SVP, Research, James Legg will be presenting a poster.

- [CRUK-AACR Joint Conference on Engineering and Physical Sciences in Oncology 2019](#), 15-17 October, London, UK

CRUK-AACR Joint Conference on Engineering and Physical Sciences in Oncology brings together cancer researchers and leading scientists from engineering and physical sciences backgrounds to explore new ways to transform our understanding of biology and to better detect and treat cancer.

Crescendo's SVP, Research, James Legg will be presenting.

- [Festival of Biologics: World Immunotherapy Congress 2019](#), 15-17 October, Basel, Switzerland

The Festival of Biologics hosts high-level speakers from big pharma, biotech, academia, regulatory bodies, investor groups, and associations, discussing topics representing key challenges within their industries, new data, case studies and research.

Crescendo's Senior Director, Early Discovery, Colette Johnston and Principal Scientist Carolyn Edwards will be presenting.

- [2nd European Oncology and Immuno-Oncology Drug Discovery Symposium](#), 22 October, Basel, Switzerland

The European Oncology and Immuno-Oncology Drug Discovery Symposium gathers industry experts to discuss how to overcome preclinical development hurdles and accelerate transition through clinical trials.

Crescendo's Senior Scientist – Translational Sciences, Jayesh Majithiya will be presenting.



- [SELECTBIO: Immuno-Oncology Europe 2019](#), 28-29 October, Rotterdam, The Netherlands

The SELECTBIO Immuno-Oncology Europe Conference brings together key opinion leaders in the immunotherapy and tumour immunology fields to address the most up-to-date strategies for immune therapy and means by which immunotherapies may be rationally combined with the more traditional anti-cancer therapeutics.

Crescendo's SVP, Research, James Legg will be presenting.

-Ends-

For more information, please contact:

Crescendo Biologics Theodora Harold, CEO	Tel: 44 (0)1223 497140 info@crescendobiologics.com
Instinctif Partners Melanie Toyne-Sewell / Phil Marriage / Nathan Billis	Tel: 44 (0)20 7457 2020 crescendo@instinctif.com

Notes to Editors

About Crescendo Biologics

Crescendo Biologics is a T cell enhancing company. Crescendo develops potent, truly differentiated Humabody® therapeutics with a focus on innovative, targeted T cell approaches in oncology.

Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel CD137-PSMA-HSA trispecific for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity and is on track to enter the clinic in 2020.

The Company's ability to develop multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® V_H). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional IgG approaches. Humabody®-based formats can also be applied across a range of non-cancer indications.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.

For more information, please visit the website: www.crescendobiologics.com